Prognostic and Predictive Factors for Renal Cell Carcinoma
| Autor: | Marc Campayo, Olatz Etxanitz, Marta Guix, Nuria Sala, Roma Bastus, Enrique Gallardo, Sergi Castillo, Cristina Suarez |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Oncology Cancer Research medicine.medical_specialty medicine.medical_treatment Individualized treatment urologic and male genital diseases Malignancy 03 medical and health sciences 0302 clinical medicine Renal cell carcinoma Internal medicine medicine Carcinoma Humans Pharmacology (medical) Carcinoma Renal Cell Chemotherapy business.industry Molecular pathogenesis Prognosis medicine.disease Kidney Neoplasms Clinical Practice 030104 developmental biology 030220 oncology & carcinogenesis Hormonal therapy business |
| Zdroj: | Targeted Oncology. 13:309-331 |
| ISSN: | 1776-260X 1776-2596 |
| DOI: | 10.1007/s11523-018-0557-2 |
| Popis: | Metastatic renal cell carcinoma (mRCC) is an incurable malignancy, characterized by its resistance to traditional chemotherapy, radiation, and hormonal therapy. Treatment perspectives and prognosis of patients with mRCC have been significantly improved by advances in the understanding of its molecular pathogenesis, which have led to the development of targeted therapeutics. Different molecular factors derived from the tumor or the host detected in both tissue or serum could be predictive of therapeutic benefit. Some of them suggest a rational selection of patients to be treated with certain therapies, though none have been validated for routine use. This article provides an overview of both clinical and molecular factors associated with predictive or prognostic value in mRCC and emphasizes that both should be considered in parallel to provide the most appropriate, individualized treatment and achieve the best outcomes in clinical practice. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink